Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Tevogen Bio (NASDAQ: TVGN) announced that Founder and CEO Dr. Ryan Saadi has donated 10,000 shares of his personal common stock to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235. The donation, conducted under SEC Rule 144, aims to support the non-profit organization's community initiatives, including D.A.R.E. programs, Explorer programs, and assistance to families of fallen and injured police officers.
Dr. Saadi will not receive any proceeds from the securities disposal. The company's press release also included extensive forward-looking statements regarding Tevogen's research, manufacturing capabilities, and development of treatments for infectious diseases and cancer.
Tevogen Bio (NASDAQ: TVGN) ha annunciato che il fondatore e CEO, il dott. Ryan Saadi, ha donato 10.000 azioni del suo patrimonio personale alla Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235. La donazione, effettuata ai sensi della Rule 144 della SEC, è destinata a sostenere le iniziative comunitarie dell'organizzazione no-profit, inclusi i programmi D.A.R.E., i programmi Explorer e l'assistenza alle famiglie degli agenti caduti o feriti.
Il dott. Saadi non riceverà alcun provento dalla cessione dei titoli. Il comunicato stampa dell'azienda includeva inoltre ampie dichiarazioni previsionali relative alla ricerca, alle capacità di produzione e allo sviluppo di terapie di Tevogen per malattie infettive e cancro.
Tevogen Bio (NASDAQ: TVGN) anunció que el fundador y CEO, el Dr. Ryan Saadi, ha donado 10.000 acciones de su patrimonio personal a la Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235. La donación, realizada conforme a la Regla 144 de la SEC, tiene como objetivo apoyar las iniciativas comunitarias de la organización sin fines de lucro, incluidos los programas D.A.R.E., los programas Explorer y la ayuda a las familias de policías caídos o heridos.
El Dr. Saadi no recibirá ningún ingreso por la enajenación de los valores. El comunicado de prensa de la compañía también incluyó extensas declaraciones prospectivas sobre la investigación, las capacidades de fabricación y el desarrollo de tratamientos de Tevogen para enfermedades infecciosas y el cáncer.
Tevogen Bio (NASDAQ: TVGN)는 창업자 겸 CEO인 Dr. Ryan Saadi가 개인 소유의 보통주 10,000주를 Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235에 기부했다고 발표했습니다. 해당 기부는 SEC 규정 Rule 144에 따라 이루어졌으며, D.A.R.E. 프로그램, Explorer 프로그램, 순직 및 부상 경찰관 가족 지원 등 비영리 단체의 지역사회 활동을 지원하는 것을 목적으로 합니다.
Dr. Saadi는 해당 증권 처분으로부터 어떠한 수익도 받지 않습니다. 회사의 보도자료에는 또한 Tevogen의 감염병 및 암 치료제 개발, 연구 및 제조 역량에 관한 광범위한 전망성 진술이 포함되어 있었습니다.
Tevogen Bio (NASDAQ: TVGN) a annoncé que le fondateur et PDG, le Dr Ryan Saadi, a fait don de 10 000 actions de son portefeuille personnel à la Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235. Le don, effectué conformément à la règle 144 de la SEC, vise à soutenir les initiatives communautaires de l'association à but non lucratif, notamment les programmes D.A.R.E., les programmes Explorer et l'aide aux familles d'agents décédés ou blessés.
Le Dr Saadi ne recevra aucun produit de la cession des titres. Le communiqué de presse de la société comportait également de nombreuses déclarations prospectives concernant la recherche, les capacités de fabrication et le développement par Tevogen de traitements contre les maladies infectieuses et le cancer.
Tevogen Bio (NASDAQ: TVGN) gab bekannt, dass Gründer und CEO Dr. Ryan Saadi 10.000 Aktien seines persönlichen Stammaktienbestands an die Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235 gespendet hat. Die Spende, durchgeführt gemäß SEC Rule 144, soll die gemeinnützigen Initiativen der Organisation unterstützen, einschließlich D.A.R.E.-Programme, Explorer-Programme und Hilfe für Familien gefallener oder verletzter Polizisten.
Dr. Saadi wird aus der Veräußerung der Wertpapiere keinerlei Erlöse erhalten. Die Pressemitteilung des Unternehmens enthielt außerdem umfangreiche zukunftsgerichtete Aussagen zu Tevogens Forschung, Produktionskapazitäten und der Entwicklung von Behandlungen für Infektionskrankheiten und Krebs.
- None.
- None.
WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235.
The Warren Township P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contributes to the D.A.R.E. and Explorer programs, provides assistance to families of fallen and injured police officers, and works to foster a strong relationship with Warren Township residents as well as P.B.A. Locals across New Jersey.
“The Warren Township Honorary P.B.A. plays an important role in strengthening the bond between law enforcement and our community,” said Dr. Saadi. “I am honored to contribute in a meaningful way to support its mission and the individuals who dedicate themselves to public service.”
The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi will not receive any proceeds from the disposal of the securities.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
How many shares did Tevogen Bio's CEO donate to Warren Township P.B.A.?
What is the purpose of the Warren Township P.B.A. Local 235?
Will Tevogen's CEO receive any proceeds from the share donation?
What SEC rule governs the share donation by Tevogen's CEO?
